blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2978747

EP2978747 - BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.02.2018
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  20.03.2017
FormerGrant of patent is intended
Status updated on  16.02.2017
FormerRequest for examination was made
Status updated on  03.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
SANOFI
54, rue La Boétie
75008 Paris / FR
[2016/05]
Inventor(s)01 / RUF, Sven
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
02 / SADOWSKI, Thorsten
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
03 / WIRTH, Klaus
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
04 / SCHREUDER, Herman
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
05 / BUNING, Christian
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
06 / KALLUS, Christopher
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
07 / STROBEL, Hartmut
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
08 / WEHLAN, Hermut
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main / DE
 [2016/05]
Representative(s)Essler, Frank, et al
Sanofi-Aventis Deutschland GmbH
Global Intellectual Property Department
Industriepark Höchst
Gebäude K 703
65926 Frankfurt am Main / DE
[2016/05]
Application number, filing date14712312.926.03.2014
[2016/05]
WO2014EP56016
Priority number, dateEP2013030540228.03.2013         Original published format: EP 13305402
[2016/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014154727
Date:02.10.2014
Language:EN
[2014/40]
Type: A1 Application with search report 
No.:EP2978747
Date:03.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 02.10.2014 takes the place of the publication of the European patent application.
[2016/05]
Type: B1 Patent specification 
No.:EP2978747
Date:19.04.2017
Language:EN
[2017/16]
Search report(s)International search report - published on:EP02.10.2014
ClassificationIPC:C07D263/32, C07D271/10, C07D277/30, C07D413/10, A61K31/426, A61P9/00, A61P11/08, A61P19/02, A61P23/00
[2016/05]
CPC:
C07D263/32 (EP,CN,US); C07D413/14 (EP,CN,US); A61P1/16 (EP);
A61P11/00 (EP); A61P11/06 (EP); A61P11/08 (EP);
A61P13/12 (EP); A61P19/02 (EP); A61P23/00 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P29/00 (EP);
A61P37/02 (EP); A61P7/02 (EP); A61P7/10 (EP);
A61P9/00 (EP); A61P9/04 (EP); A61P9/10 (EP);
A61P9/12 (EP); C07D271/10 (EP,CN,US); C07D277/30 (EP,CN,US);
C07D413/10 (EP,CN,US); C07D417/10 (EP,CN,US); C07D417/14 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/05]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BIARYL-PROPIONSÄURE-DERIVATE UND IHRE VERWENDUNG ALS ARZNEIMITTEL[2016/44]
English:BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS[2016/05]
French:DÉRIVÉS DE L'ACIDE PROPIONIQUE BIARYLE-ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES[2016/44]
Former [2016/05]BIARYL-PROPIONSÄURE-DERIVATE UND DEREN VERWENDUNG ALS ARZNEIMITTEL
Former [2016/05]DÉRIVÉS D'ACIDE BIARYL-PROPIONIQUE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
Entry into regional phase28.10.2015National basic fee paid 
28.10.2015Designation fee(s) paid 
28.10.2015Examination fee paid 
Examination procedure28.10.2015Examination requested  [2016/05]
29.02.2016Amendment by applicant (claims and/or description)
20.10.2016Communication of intention to grant the patent
02.02.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.02.2017Communication of intention to grant the patent
01.03.2017Fee for grant paid
01.03.2017Fee for publishing/printing paid
01.03.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.10.2016
Opposition(s)22.01.2018No opposition filed within time limit [2018/13]
Fees paidRenewal fee
10.03.2016Renewal fee patent year 03
10.03.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.03.2014
AL19.04.2017
AT19.04.2017
CY19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
MC19.04.2017
MK19.04.2017
PL19.04.2017
PT19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
TR19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
[2020/34]
Former [2020/31]HU26.03.2014
AT19.04.2017
CY19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
MC19.04.2017
MK19.04.2017
PL19.04.2017
PT19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
TR19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2020/30]HU26.03.2014
AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
MC19.04.2017
PL19.04.2017
PT19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
TR19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2020/28]AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
MC19.04.2017
PL19.04.2017
PT19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
TR19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2020/15]AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
MC19.04.2017
PL19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
TR19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2018/52]AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
MC19.04.2017
PL19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2018/25]AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
PL19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SI19.04.2017
SK19.04.2017
SM19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2018/11]AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
PL19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SK19.04.2017
SM19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2018/10]AT19.04.2017
CZ19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
PL19.04.2017
RO19.04.2017
RS19.04.2017
SE19.04.2017
SK19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2018/09]AT19.04.2017
DK19.04.2017
EE19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
PL19.04.2017
RS19.04.2017
SE19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2017/50]AT19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
LV19.04.2017
PL19.04.2017
RS19.04.2017
SE19.04.2017
BG19.07.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Former [2017/49]AT19.04.2017
ES19.04.2017
FI19.04.2017
HR19.04.2017
LT19.04.2017
NO19.07.2017
GR20.07.2017
IS19.08.2017
Cited inInternational search[AD]WO2011092187  (SANOFI SA [FR], et al) [AD] 1-9 * page 1, line 5 - line 14; claim 1 *;
 [AD]WO2012101199  (SANOFI SA [FR], et al) [AD] 1-9* page 1, line 5 - line 14; claim 1 *
by applicantUS2004072802
 WO2004056815
 JP2005145839
 WO2006076202
 WO2009080226
 WO2009080227
 WO2011092187
 WO2012101197
 WO2012101199
 WO2013014204
 WO2013014205
 WO2013072327
 WO2013072328
    - A. D'AZZO ET AL., THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE, (1995), vol. 2, pages 2835 - 2837
    - G. RUDENKO ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 621 - 625
    - N. J. GALJART ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 14754 - 14762
    - R. J. ROTTIER ET AL., HUM. MOL. GENET., (1998), vol. 7, pages 1787 - 1794
    - V. SEYRANTEPE ET AL., CIRCULATION, (2008), vol. 117, pages 1973 - 1981
    - M. HIRAIWA, CELL. MOL. LIFE SCI., (1999), vol. 56, pages 894 - 907
    - M. SAITO ET AL., INT. J. TISS. REAC., (1995), vol. 17, pages 181 - 190
    - W. L. HANNA ET AL., J. IMMUNOL., (1994), vol. 153, pages 4663 - 4672
    - H. OSTROWSKA, THROMB. RES., (1997), vol. 86, pages 393 - 404
    - 0. SOHMA ET AL., PEDIATR. NEUROL., (1999), vol. 20, pages 210 - 214
    - N. M. STAMATOS ET AL., FEBS J., (2005), vol. 272, pages 2545 - 2556
    - A. HINEK, BIOL. CHEM., (1996), vol. 377, pages 471 - 480
    - H. ITO ET AL., BR. J. PHARMACOL., (1999), vol. 126, pages 613 - 620
    - I. HAJASHI ET AL., BR. J. PHARMACOL., (2000), vol. 131, pages 820 - 826
    - J. CHAO ET AL., BIOL. CHEM., (2006), vol. 387, pages 665 - 75
    - MADEDDU ET AL., NAT. CLIN. PRACT. NEPHROL., (2007), vol. 3, pages 208 - 221
    - F. MARCEAU ET AL., NAT. REV. DRUG DISCOV., (2004), vol. 3, pages 845 - 852
    - H. OSTROWSKA ET AL., J. CARDIOVASC. PHARMACOL., (2005), vol. 45, pages 348 - 353
    - C. PLANES ET AL., CURR. TOP. DEV. BIOL., (2007), vol. 78, pages 23 - 46
    - J. MED. CHEM., (2012), vol. 55, no. 17, pages 7636 - 7649
    - M. MORA, CURRENT ORGANIC CHEMISTRY, (2012), pages 1128 - 1150
    - W. LINZ ET AL., JRAAS (JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, (2006), vol. 7, pages 155 - 161
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.